All Stories

  1. Animal models for COVID-19
  2. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing
  3. An In Vitro Microneutralization Assay for SARS‐CoV‐2 Serology and Drug Screening
  4. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
  5. Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial
  6. Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts
  7. Viral Determinants in H5N1 Influenza A Virus Enable Productive Infection of HeLa Cells
  8. Vaccination With Viral Vectors Expressing Chimeric Hemagglutinin, NP and M1 Antigens Protects Ferrets Against Influenza Virus Challenge
  9. Innate Immune Response to Influenza Virus at Single-Cell Resolution in Human Epithelial Cells Revealed Paracrine Induction of Interferon Lambda 1
  10. Host-Specific NS5 Ubiquitination Determines Yellow Fever Virus Tropism
  11. Sequential Immunization With Live-Attenuated Chimeric Hemagglutinin-Based Vaccines Confers Heterosubtypic Immunity Against Influenza A Viruses in a Preclinical Ferret Model
  12. Diminished B-Cell Response After Repeat Influenza Vaccination
  13. Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance
  14. A Live-Attenuated Prime, Inactivated Boost Vaccination Strategy with Chimeric Hemagglutinin-Based Universal Influenza Virus Vaccines Provides Protection in Ferrets: A Confirmatory Study
  15. Microbiome disturbance and resilience dynamics of the upper respiratory tract in response to influenza A virus infection in humans and ferrets
  16. Analyses of Cellular Immune Responses in Ferrets Following Influenza Virus Infection
  17. Assessment of Influenza Virus Hemagglutinin Stalk-Specific Antibody Responses
  18. Timing of Influenza Vaccine Response in Patients That Receive Autologous Hematopoietic Cell Transplantation
  19. Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins
  20. A point mutation in the polymerase protein PB2 allows a reassortant H9N2 influenza isolate of wild-bird origin to replicate in human cells
  21. ICOS+PD-1+CXCR3+ T follicular helper cells contribute to the generation of high-avidity antibodies following influenza vaccination
  22. H7N9 influenza virus neutralizing antibodies that possess few somatic mutations
  23. Active opioid use does not attenuate the humoral responses to inactivated influenza vaccine
  24. Hemagglutinin Stalk Immunity Reduces Influenza Virus Replication and Transmission in Ferrets
  25. Meta- and Orthogonal Integration of Influenza “OMICs” Data Defines a Role for UBR4 in Virus Budding
  26. Interactive Big Data Resource to Elucidate Human Immune Pathways and Diseases
  27. Human Dendritic Cell Response Signatures Distinguish 1918, Pandemic, and Seasonal H1N1 Influenza Viruses
  28. Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency
  29. The Nucleoprotein of Newly Emerged H7N9 Influenza A Virus Harbors a Unique Motif Conferring Resistance to Antiviral Human MxA
  30. A dual vaccine against influenza & Alzheimer's disease failed to enhance anti-β-amyloid antibody responses in mice with pre-existing virus specific memory
  31. Influenza A Virus Transmission Bottlenecks Are Defined by Infection Route and Recipient Host
  32. Distinct Patterns of B-Cell Activation and Priming by Natural Influenza Virus Infection Versus Inactivated Influenza Vaccination
  33. Immunologic Characterization of a Rhesus Macaque H1N1 Challenge Model for Candidate Influenza Virus Vaccine Assessment
  34. Effect of Cholecalciferol Supplementation on Inflammation and Cellular Alloimmunity in Hemodialysis Patients: Data from a Randomized Controlled Pilot Trial
  35. The origin of the PB1 segment of swine influenza A virus subtype H1N2 determines viral pathogenicity in mice
  36. Differential Requirement for the IKKβ/NF-κB Signaling Module in Regulating TLR- versus RLR-Induced Type 1 IFN Expression in Dendritic Cells
  37. Human Responses to Influenza Vaccination Show Seroconversion Signatures and Convergent Antibody Rearrangements
  38. Mucosal Polyinosinic-Polycytidylic Acid Improves Protection Elicited by Replicating Influenza Vaccines via Enhanced Dendritic Cell Function and T Cell Immunity
  39. Model of influenza A virus infection: Dynamics of viral antagonism and innate immune response
  40. Turkey Versus Guinea Pig Red Blood Cells: Hemagglutination Differences Alter Hemagglutination Inhibition Responses Against Influenza A/H1N1
  41. Suppression of Innate Immunity by Orthomyxoviruses
  42. Distinct Cross-reactive B-Cell Responses to Live Attenuated and Inactivated Influenza Vaccines
  43. Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine Correlate With the Kinetics and Magnitude of Interferon Signaling in Children
  44. Divergent H7 Immunogens Offer Protection from H7N9 Virus Challenge
  45. Assessment of Influenza Virus Hemagglutinin Stalk-Based Immunity in Ferrets
  46. One-shot vaccination with an insect cell-derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge
  47. MicroRNA-based strategy to mitigate the risk of gain-of-function influenza studies
  48. Hemagglutinin Stalk-Based Universal Vaccine Constructs Protect against Group 2 Influenza A Viruses
  49. Protection against Lethal Influenza with a Viral Mimic
  50. Glycosylations in the Globular Head of the Hemagglutinin Protein Modulate the Virulence and Antigenic Properties of the H1N1 Influenza Viruses
  51. Recombinant IgA Is Sufficient To Prevent Influenza Virus Transmission in Guinea Pigs
  52. Substitutions T200A and E227A in the Hemagglutinin of Pandemic 2009 Influenza A Virus Increase Lethality but Decrease Transmission
  53. Induction of ICOS+CXCR3+CXCR5+ TH Cells Correlates with Antibody Responses to Influenza Vaccination
  54. H3N2 Influenza Virus Infection Induces Broadly Reactive Hemagglutinin Stalk Antibodies in Humans and Mice
  55. Accumulation of CD11b+Gr-1+ cells in the lung, blood and bone marrow of mice infected with highly pathogenic H5N1 and H1N1 influenza viruses
  56. Species-Specific Inhibition of RIG-I Ubiquitination and IFN Induction by the Influenza A Virus NS1 Protein
  57. Mouse Dendritic Cell (DC) Influenza Virus Infectivity Is Much Lower than That for Human DCs and Is Hemagglutinin Subtype Dependent
  58. Human Monoclonal Antibodies to Pandemic 1957 H2N2 and Pandemic 1968 H3N2 Influenza Viruses
  59. Influenza Viruses Expressing Chimeric Hemagglutinins: Globular Head and Stalk Domains Derived from Different Subtypes
  60. Suppression of the antiviral response by an influenza histone mimic
  61. Major Histocompatibility Complex Class II Expression and Hemagglutinin Subtype Influence the Infectivity of Type A Influenza Virus for Respiratory Dendritic Cells
  62. The M Segment of the 2009 New Pandemic H1N1 Influenza Virus Is Critical for Its High Transmission Efficiency in the Guinea Pig Model
  63. Host- and Strain-Specific Regulation of Influenza Virus Polymerase Activity by Interacting Cellular Proteins
  64. Programming the magnitude and persistence of antibody responses with innate immunity
  65. The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease
  66. Macaque Proteome Response to Highly Pathogenic Avian Influenza and 1918 Reassortant Influenza Virus Infections
  67. Oseltamivir-Resistant Variants of the 2009 Pandemic H1N1 Influenza A Virus Are Not Attenuated in the Guinea Pig and Ferret Transmission Models
  68. NF- B RelA Subunit Is Crucial for Early IFN-  Expression and Resistance to RNA Virus Replication
  69. Extrapulmonary tissue responses in cynomolgus macaques (Macaca fascicularis) infected with highly pathogenic avian influenza A (H5N1) virus
  70. Complete-Proteome Mapping of Human Influenza A Adaptive Mutations: Implications for Human Transmissibility of Zoonotic Strains
  71. Innate immune evasion strategies of influenza viruses
  72. 1918 and 2009 H1N1 influenza viruses are not pathogenic in birds
  73. Matrix Protein 2 of Influenza A Virus Blocks Autophagosome Fusion with Lysosomes
  74. The NS1 Protein of the 1918 Pandemic Influenza Virus Blocks Host Interferon and Lipid Metabolism Pathways
  75. Influenza A Virus NS1 Targets the Ubiquitin Ligase TRIM25 to Evade Recognition by the Host Viral RNA Sensor RIG-I
  76. Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus
  77. Experimental Infection of Pigs with the Human 1918 Pandemic Influenza Virus
  78. Live Attenuated Influenza Viruses Containing NS1 Truncations as Vaccine Candidates against H5N1 Highly Pathogenic Avian Influenza
  79. The Unique IR2 Protein of Equine Herpesvirus 1 Negatively Regulates Viral Gene Expression
  80. The EICP27 protein of equine herpesvirus 1 is recruited to viral promoters by its interaction with the immediate-early protein
  81. A Negative Regulatory Element (Base Pairs −204 to −177) of the EICP0 Promoter of Equine Herpesvirus 1 Abolishes the EICP0 Protein's trans-Activation of Its Own Promoter
  82. The equine herpesvirus 1 EICP27 protein enhances gene expression via an interaction with TATA box-binding protein
  83. Direct interaction of TFIIB and the IE protein of equine herpesvirus 1 is required for maximal trans-activation function
  84. Interaction of the Equine Herpesvirus 1 EICP0 Protein with the Immediate-Early (IE) Protein, TFIIB, and TBP May Mediate the Antagonism between the IE and EICP0 Proteins
  85. Mapping the Sequences That Mediate Interaction of the Equine Herpesvirus 1 Immediate-Early Protein and Human TFIIB